3176 Stock Overview
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan.
No risks detected for 3176 from our risk checks.
Medigen Biotechnology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$47.30|
|52 Week High||NT$90.00|
|52 Week Low||NT$44.40|
|1 Month Change||-16.73%|
|3 Month Change||-9.91%|
|1 Year Change||-30.65%|
|3 Year Change||-35.03%|
|5 Year Change||-12.25%|
|Change since IPO||147.64%|
Recent News & Updates
|3176||TW Biotechs||TW Market|
Return vs Industry: 3176 underperformed the TW Biotechs industry which returned 7.3% over the past year.
Return vs Market: 3176 underperformed the TW Market which returned -0.7% over the past year.
|3176 Average Weekly Movement||5.1%|
|Biotechs Industry Average Movement||5.2%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.2%|
|10% least volatile stocks in TW Market||2.2%|
Stable Share Price: 3176 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.
About the Company
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with radiation for the treatment of esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States.
Medigen Biotechnology Fundamentals Summary
|3176 fundamental statistics|
Is 3176 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|3176 income statement (TTM)|
|Cost of Revenue||NT$1.48b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.50|
|Net Profit Margin||-1.66%|
How did 3176 perform over the long term?See historical performance and comparison
Is Medigen Biotechnology undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3176 (NT$47.3) is trading below our estimate of fair value (NT$153.47)
Significantly Below Fair Value: 3176 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3176 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW Biotechs industry average.
PE vs Market: 3176 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3176's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3176 is good value based on its Price-To-Book Ratio (2.7x) compared to the TW Biotechs industry average (3.8x).
How is Medigen Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Medigen Biotechnology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3176 is currently unprofitable.
Growing Profit Margin: 3176 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3176 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
Accelerating Growth: Unable to compare 3176's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3176 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 3176 has a negative Return on Equity (16.03%), as it is currently unprofitable.
How is Medigen Biotechnology's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 3176's short term assets (NT$4.7B) exceed its short term liabilities (NT$902.2M).
Long Term Liabilities: 3176's short term assets (NT$4.7B) exceed its long term liabilities (NT$790.8M).
Debt to Equity History and Analysis
Debt Level: 3176 has more cash than its total debt.
Reducing Debt: 3176's debt to equity ratio has reduced from 31.7% to 10.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 3176 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 3176 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 10.5% per year.
What is Medigen Biotechnology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3176's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 3176's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3176's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3176's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 3176 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Stanley Chang (62 yo)
Dr. Shi-Chung Chang, also known as Stanley, MD, Ph D., serves as the Chairman and Chief Executive Officer of Medigen Biotechnology Corporation. Dr. Chang is a Urological surgeon by training, and was former...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medigen Biotechnology Corp.'s employee growth, exchange listings and data sources
- Name: Medigen Biotechnology Corp.
- Ticker: 3176
- Exchange: TPEX
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$6.592b
- Shares outstanding: 139.37m
- Website: https://www.medigen.com.tw
- Medigen Biotechnology Corp.
- No.3, Park Street
- 14th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/23 00:00|